We have previously reported that primitive normal hematopoietic cells detectable as long-term culture-initiating cells (Ph-LTC-IC) are present at high levels in the blood of some patients with chronic myeloid leukemia (CML). We now show that this population can be expanded several-fold when highly purified CD34+CD38 cells isolated from the blood of such patients are cultured for 10 days in a serum-free medium containing 100 ng/mL of Flt3-ligand and Steel factor and 20 ng/mL of interleukin-3 (IL-3) and IL-6, and granulocyte colony-stimulating factor. In similar cultures initiated with CD34+CD38 cells from CML blood samples in which all of the LTC-IC were leukemic (Ph+), Ph+ LTC-IC activity was rapidly lost both in the presence and absence of admixed CD34+CD38 cells isolated from normal marrow. Conversely, the ability of normal LTC-IC to expand their numbers was shown to be independent of the presence of Ph+LTC-IC and later types of Ph+colony-forming cell (CFC) progenitors. In contrast to the LTC-IC, CFC were consistently -a m p l i f i e d  i n  c u l t u r e s  i n i t i a t e d  w i t h  C M L - d e r i v e d -CD34+CD38 cells and the additional CFC present after 10 days were, like the starting population of CFC, almost exclusively Ph+ regardless of the genotype(s) of the LTC-IC in the original CML samples. Amplification of the Ph+CFC population in these cultures showed the same factor dependence as previously demonstrated for the in vitro expansion of CFC from normal marrow CD34+CD38 cells. Ph+LTC-IC disappeared regardless of the cytokines present. Taken together these findings support a model of CML in which the leukemic stem cells are characterized by a decreased probability of self-renewal and an increased probability of differentiation. In addition, they suggest new opportunities for improving the treatment of CML using strategies that require autologous stem cell rescue.

CHRONIC MYELOID leukemia (CML) is a hematologic malignancy that is believed to arise in a hematopoietic stem cell with lymphoid and myeloid differentiation potential.1 The disease is characterized biologically by the deregulated overgrowth of the marrow by a multilineage clone of cells, all of which are marked by the presence of a novel BCR-ABL fusion gene.2 The formation of this new gene usually involves a reciprocal translocation between the long arms of chromosomes 9 and 22 leading to the formation of a unique chromosome identified as the Philadelphia chromosome (Ph).3 The transcription of the BCR-ABL gene leads to the synthesis of a new protein that has been shown to have transforming properties in a variety of model systems.4-9 In patients, a marked expansion of the leukemic (Ph+) clone is accompanied by an excessive production of mature granulocytes and a concomitant suppression of normal hematopoiesis. Nevertheless, a residual population of primitive normal (Ph) cells persists in many patients.10-13 These cells may be found in the blood in patients studied soon after diagnosis14 or during the period of endogenous hematopoietic recovery that follows myelo-reductive therapy15 and include cells with functional properties associated with stem cells; ie, cells with transplantable hematopoietic regenerative potential16 and that are able to produce in vitro colony-forming cells (CFC) for at least 5 weeks in cocultures containing adherent stromal cell feeder layers.10,14 The latter are referred to as long-term culture-initiating cells (LTC-IC).17 In addition to PhLTC-IC, variable numbers of Ph+LTC-IC are also found in the marrow and blood of CML patients.13,14 However, at all later stages of myeloid differentiation Ph+ cells typically predominate.14 18 

Normal and leukemic LTC-IC are not readily distinguished with respect to their expression of most surface markers thus far examined. These include CD34, CD71, CD38, and Thy-1, whose upregulation or downregulation has been associated with a primitive state in analyses of hematopoietic tissues from normal individuals.19-23 Therefore, isolation of various subfractions of the CD34+ cells present in CML blood samples (eg, the CD34+CD71CD38subpopulation) can provide a source of cells that is highly enriched in LTC-IC, but their predominant genotype remains the same as in the original unfractionated blood sample and this can be either Ph or Ph+.14 Even where differences in the relative proportion of leukemic and normal LTC-IC in a given subpopulation have been reported (eg, as in the case of CD34+HLA-DRcells24,25 ), phenotypic heterogeneity among both types of LTC-IC exists.25,26 Thus, isolation of a particular phenotype may not provide the resolving power necessary to obtain clinically useful CML autografts. An alternative purging approach under current clinical evaluation27,28 is based on the rapid loss of Ph+LTC-IC that is seen when CML blood or marrow cells are cocultured on stroma under conditions that maintain (but do not expand) normal LTC-IC.29 Because we recently found that LTC-IC from normal marrow can be significantly expanded in cultures containing soluble cytokines,23 30 it was of interest to determine whether the PhLTC-IC often present in isolates of CML cells could also be expanded under these conditions and, if so, whether this would be accompanied by an increase or decrease in Ph+LTC-IC numbers.

Heparinized blood samples were obtained with informed consent from nine CML patients undergoing routine hematologic assessment. (For convenience, patients are referred to by the same number throughout the Tables in the Results.) All had elevated white blood cell (WBC) counts and were at various stages in the course of their disease as described in detail previously.14 Normal cadaveric bone marrow cells were purchased from the Northwest Tissue Co (Seattle, WA) and cryopreserved before use. All procedures for the isolation, cryopreservation, and thawing of light-density (<1.077 g/mL) cells followed by the sorting by fluorescence-activated cell sorting (FACS) of CD34+CD38 populations and their subsequent assessment for Ph+ or PhCFC and LTC-IC content before and after culture at 5 × 103 cells/mL in serum-free media (StemCell Technologies Inc, Vancouver, BC, Canada) containing various cytokine supplements were the same as previously described, including the use of a 6-week CFC output on murine fibroblast feeders engineered to produce human interleukin-3 (IL-3), granulocyte colony-stimulating factor (G-CSF), and Steel factor (SF) to measure human LTC-IC.14,23,30 31 

Rapid loss of Ph+LTC-IC activity with expansion of Ph+CFC in serum-free cultures of CD34+CD38 CML cells.Table 1 shows the results of a first series of experiments to investigate how the number of Ph+LTC-IC (and CFC) might change in cultures of highly purified CD34+CD38 CML cells maintained for 10 days under serum-free conditions in the presence 100 ng/mL of Flt3-ligand (FL) and SF, plus 20 ng/mL of IL-3, IL-6, and G-CSF. This combination of cytokines was used because it had been previously found to stimulate a large expansion of both LTC-IC (≈25-fold) and CFC (≈800-fold) in analogous cultures of CD34+CD38 cells isolated from normal marrow.30 As shown in Table 1, these conditions supported a rapid expansion of the CFC -p o p u l a t i o n  i n  c u l t u r e s  i n i t i a t e d  w i t h  e x c l u s i v e l y -Ph+CD34+CD38 cells (although the extent of this expansion was highly variable). Interestingly, in the same 10-day-old CML cultures, Ph+LTC-IC activity was consistently lost (no detectable LTC-IC activity in cultures from three patients, ie, a >1,000-fold decrease, with an ≈50-fold reduction measured in the fourth case).

Table 1.

Loss of Leukemic (Ph+) LTC-IC Activity in 10-Day Suspension Cultures of CD34+CD38 CML Blood Cells

CML No.LTC-IC (per 100 input cells)CFC (per 100 input cells)
Day 0Day 10Fold Change*Day 0Day 10Expansion*
1a 27 <0.002 <0.000074 x 196 65 x 
1b 45 <0.0002 <0.000004 x 742 250 x 
2a <0.002 <0.001 x 144 16 x 
2b <0.001 <0.0005  —  2,940 330 x 
<0.001 <0.0001 x 11 990 90 x 
0.2 0.022 x 12 126 10 x 
CML No.LTC-IC (per 100 input cells)CFC (per 100 input cells)
Day 0Day 10Fold Change*Day 0Day 10Expansion*
1a 27 <0.002 <0.000074 x 196 65 x 
1b 45 <0.0002 <0.000004 x 742 250 x 
2a <0.002 <0.001 x 144 16 x 
2b <0.001 <0.0005  —  2,940 330 x 
<0.001 <0.0001 x 11 990 90 x 
0.2 0.022 x 12 126 10 x 

Highly purified CD34+CD38 cells (≥99% pure) were isolated by FACS from selected cryopreserved samples of light density (<1.077 g/mL) blood cells of 4 different CML patients because they had been previously shown to contain elevated numbers of exclusively Ph+ LTC-IC and CFC. The cells were incubated for 10 days at 37°C in a serum-free medium containing FL and SF at 100 ng/mL each, and IL-3, IL-6, and G-CSF at 20 ng/mL each. At the end of 10 days, LTC-IC and CFC assays were performed on the harvested cells.

*

Calculated as Day 10 value ÷ Day 0 value.

b experiments were set up with a separate thawed aliquot of cells from the same patient sample used for the “a” experiments and represent the control cultures (CML cells only) set up in parallel with the mixing experiments reported in Table 6.

Because we had previously found that different cytokine combinations are required to maximize the in vitro expansion of CFC and LTC-IC from normal CD34+CD38 marrow cells,30 the possibility that the various component cytokines, either alone or in other combinations, might have had a different effect on Ph+CD34+CD38 cells was investigated. However, as shown in Table 2, the same rapid loss of Ph+LTC-IC activity seen with the five-cytokine cocktail (Table 1) occurred regardless of the cytokine(s) added. On the other hand, the results for Ph+CFC expansion (Table 3) paralleled those previously obtained for the expansion of CFC in cultures of normal CD34+CD38 marrow cells30; ie, IL-3 was the most effective single cytokine that could stimulate an amplification of the Ph+CFC population, and the combination of FL plus SF and IL-3, although more effective than any one of these three alone, was not as effective as when IL-6 and G-CSF were also present (compare results in Table 3 with those shown in Table 1).

Table 2.

Effect of Various Cytokines on the Loss of Leukemic (Ph+) LTC-IC Activity in 10-Day Cultures of CD34+CD38 CML Blood Cells

CML No.*Day 0 LTC-ICDay 10 LTC-IC (per 100 input cells)
(per 100 input cells)FLSFIL-3FL, SF, IL-3
27 <0.002 <0.002 <0.002 <0.002 
<0.002 <0.002 <0.002 <0.002 
<0.001 <0.001 <0.001 0.001 
0.3 0.1 0.1 0.2 
CML No.*Day 0 LTC-ICDay 10 LTC-IC (per 100 input cells)
(per 100 input cells)FLSFIL-3FL, SF, IL-3
27 <0.002 <0.002 <0.002 <0.002 
<0.002 <0.002 <0.002 <0.002 
<0.001 <0.001 <0.001 0.001 
0.3 0.1 0.1 0.2 
*

Same patient samples as in Table 1. The experiments were performed concurrently using the same general culture conditions and cytokine concentrations.

Table 3.

Expansion of Leukemic (Ph+) CFC in 10-Day Cultures of CD34+CD38 CML Blood Cells

CML No.3-150Day 0 CFCExpansion of CFC After 10 Days
(per 100 input cells)FLSFIL-3FL, SF, IL-3
12 x 17 x 22 x 31 x 
1.4 x 1.4 x 2.5 x 15 x 
11 ND ND ND 39 x 
12 2.5 x 2.8 x 4 x 4.4 x 
CML No.3-150Day 0 CFCExpansion of CFC After 10 Days
(per 100 input cells)FLSFIL-3FL, SF, IL-3
12 x 17 x 22 x 31 x 
1.4 x 1.4 x 2.5 x 15 x 
11 ND ND ND 39 x 
12 2.5 x 2.8 x 4 x 4.4 x 

Abbreviation: ND, not done.

F3-150

Same experiments as shown in Table 2.

Expansion of normal LTC-IC in cultures of CD34+CD38 cells containing various mixtures of Ph+and PhLTC-IC and CFC.Experiments were then performed to determine whether an expansion of the normal (Ph) LTC-IC seen in some CML blood samples14 could be obtained under conditions that had been found to cause a rapid decrease in detectable Ph+LTC-IC (Table 1). To investigate this question, we used a different set of five cryopreserved CML blood cell samples in which the LTC-IC had been previously found to be predominantly Ph (only PhLTC-IC detected), although the coexisting CFC were exclusively Ph+. The numbers and genotypes of the LTC-IC and CFC obtained from 10-day suspension cultures initiated with the CD34+CD38 cells isolated from these samples are shown in Tables 4 and 5, respectively. All of these cultures contained the same five-cytokine cocktail used in the experiments described in Table 1 (100 ng/mL of FL and SF, and 20 ng/mL of IL-3, IL-6, and G-CSF). In two cases (nos. 6 and 7), the PhLTC-IC had increased fourfold to fivefold by the end of the 10-day culture period. In the third case (no. 5), a fivefold increase in PhLTC-IC was obtained in a first experiment but not in a repeat experiment in which the initial yield of LTC-IC was considerably lower. In the fourth case (no. 8), the PhLTC-IC declined slightly and, in the fifth case (no. 9), where again the LTC-IC content of the starting population of CD34+CD38cells was unusually low, their numbers were not sustained. CFC numbers were expanded in all cultures and, unexpectedly, in every case, were predominantly Ph+ (Table 5). The fact that this occurred in the absence of detectable Ph+LTC-IC indicates that the new CFC present in such 10-day cultures were derived either from CD34+CD38 cells initially detectable as CFC and/or from some otherwise uncharacterized CD34+CD38 cell type that is not detectable as either a CFC or as an LTC-IC. The fact that very few PhCFC were produced in cultures that contained exclusively PhLTC-IC suggests that the majority of the expanded populations of CFC obtained within the first 10 days in cultures of normal CD34+CD38 cells30 also represent the progeny of cells that are not initially detectable as LTC-IC. However, in neither instance do these findings exclude the possibility that many (or even most) normal or Ph+LTC-IC can give rise to small numbers of CFC within 10 days under these culture conditions because such cells would represent a population too small to be detected by the level of discrimination possible by cytogenetic analysis of individual colonies.

Table 4.

Increase in Normal (Ph) LTC-IC in 10-Day Cultures of CD34+CD38 CML Blood Cells

CML No.LTC-IC (per 100 input cells)4-150
Day 0Day 10
No.% PhNo.% PhExpansion
5a 18 100 (2/2)4-151 93 100 (11/11) 5.3 x 
5b 100 (4/4) <0.03  —  <0.01 x 
102 100 (22/22) 467 100 (26/26) 4.6 x 
12 100 (17/17) 47 100 (25/25) 4.1 x 
196 100 (20/20) 87 100 (1/1) 0.4 x 
100 (4/4) <0.0004  —  <0.0002 x 
CML No.LTC-IC (per 100 input cells)4-150
Day 0Day 10
No.% PhNo.% PhExpansion
5a 18 100 (2/2)4-151 93 100 (11/11) 5.3 x 
5b 100 (4/4) <0.03  —  <0.01 x 
102 100 (22/22) 467 100 (26/26) 4.6 x 
12 100 (17/17) 47 100 (25/25) 4.1 x 
196 100 (20/20) 87 100 (1/1) 0.4 x 
100 (4/4) <0.0004  —  <0.0002 x 

Cells were incubated in a serum-free medium containing FL and SF at 100 ng/mL each, and IL-3, IL-6, and G-CSF at 20 ng/mL each.

F4-150

All LTC-IC numbers in this study were determined by dividing the total CFC detected in the 6-week-old LTC-IC assay cultures by 8 based on preliminary data suggesting that this represents the average CFC output per Ph+ LTC-IC cultured under the conditions used here (unpublished data, 1996). The corresponding average CFC output from normal cytokine-mobilized LTC-IC is 25.31 Therefore, the values shown in this table may represent overestimates of absolute Ph LTC-IC frequencies by up to threefold. However, this would be unlikely to affect the expansion values shown because we have previously shown that the CFC output per LTC-IC does not change when normal LTC-IC are expanded in cultures containing the cytokines used here.23 

F4-151

Values shown in parentheses are the numbers of LTC-IC–derived colonies scored as Ph divided by the total number of LTC-IC–derived colonies analyzed.

b experiment was set up with a separately thawed aliquot of cells from the same patient sample used for the “a” experiment and represents the control (CML cells only) set up in parallel with the mixing experiment reported in Table 6.

Table 5.

Production of Ph+ CFC From CD34+CD38 CML Blood Cells in Which All Initial LTC-IC Were Ph

CML No.CFC (per 100 input cells)
Day 0Day 10% Ph+ at Day 10Expansion
5a 13 3,870 100 (11/11)5-150 300 x 
5b5-151 1,060 100 (14/14) 180 x 
11 5,670 90 (19/21) 540 x 
340 Not done 110 x 
17 2,280 100 (4/4) 140 x 
1,060 100 (14/14) 190 x 
CML No.CFC (per 100 input cells)
Day 0Day 10% Ph+ at Day 10Expansion
5a 13 3,870 100 (11/11)5-150 300 x 
5b5-151 1,060 100 (14/14) 180 x 
11 5,670 90 (19/21) 540 x 
340 Not done 110 x 
17 2,280 100 (4/4) 140 x 
1,060 100 (14/14) 190 x 

Same experiments as in Table 4.

F5-150

Values shown in parentheses are the numbers of colonies scored as Ph+, divided by the total number of colonies analyzed.

F5-151

For explanation of a and b experiments, see footnote to Table 4.

To determine whether the different responses exhibited by Ph+ and Ph progenitors in cultures of CD34+CD38 CML blood cells might be influenced by potential interactions between Ph+ and Ph cells, a series of mixing experiments was performed. In each of these, cultures were initiated with Ph+CD34+CD38 cells isolated from different CML blood samples and then mixed with an equal number of CD34+CD38 cells obtained from a sample of marrow from a normal individual. For these experiments, additional aliquots of cells from the first two patients studied in Table 1 (nos. 1 and 2) and the first patient studied in Table 4 (no. 5) were used. The results obtained (Table 6) show no evidence of a negative effect of Ph+ cells on the ability of normal LTC-IC to be amplified in suspension cultures containing the same five-cytokine cocktail (FL, SF, IL-3, IL-6, and G-CSF) used in the described experiments previously. Conversely, the presence of CD34+CD38 cells from normal marrow had no salvaging effect on the concomitant rapid loss in vitro of Ph+LTC-IC activity.

Table 6.

The Presence of Ph+CD34+CD38 CML Cells Has No Effect on the Expansion of Normal LTC-IC in 10-Day Cocultures

Source of CML Cells Added (sex)No. of Day 10 LTC-ICNo. of Day 10 LTC-IC per 100 Input CML Cells Cultured in the Presence of 100 Normal BM Cells% Ph Day 10 LTC-ICExpansion of Normal LTC-IC6-150
per 100 Input CML Cells in the Absence of Normal BM Cells (fold change)(no. Ph/total analyzed, sex)
CML no. 1 (M) <0.025 263 100 (21/21, F) 10 x 
CML no. 2 (F) <0.025 1,125 100 (27/27, F) 42 x 
CML no. 5 (M) <0.025 1,225 97 (33/34, F)6-151 45 x 
None  450  —  17 x 
Source of CML Cells Added (sex)No. of Day 10 LTC-ICNo. of Day 10 LTC-IC per 100 Input CML Cells Cultured in the Presence of 100 Normal BM Cells% Ph Day 10 LTC-ICExpansion of Normal LTC-IC6-150
per 100 Input CML Cells in the Absence of Normal BM Cells (fold change)(no. Ph/total analyzed, sex)
CML no. 1 (M) <0.025 263 100 (21/21, F) 10 x 
CML no. 2 (F) <0.025 1,125 100 (27/27, F) 42 x 
CML no. 5 (M) <0.025 1,225 97 (33/34, F)6-151 45 x 
None  450  —  17 x 

All cultures contained CD34+CD38 cells isolated from a normal female (F) bone marrow (BM) sample and 100 ng/mL of FL and SF, and 20 ng/mL of IL-3, IL-6, and G-CSF. CD34+CD38 CML cells were added as shown.

Abbreviation: ND, not done.

F6-150

Day 10 LTC-IC value relative to number of LTC-IC in 100 input normal BM cells (=27).

F6-151

In the cocultures of normal female marrow plus CML no. 3 cells, 1 Ph+ (male) colony was found in the LTC-IC assays.

The present experiments show that previously cryopreserved, normal (Ph) LTC-IC isolated from the peripheral blood of some CML patients at diagnosis14 could be expanded several-fold when incubated for 10 days under highly defined culture conditions (Table 4), although the expansion was less than what we have seen in analogous cultures of CD34+CD38 cells isolated from the marrow of normal individuals.23,30 Further studies will be required to determine whether a reduced proliferative potential may be a generalized feature of circulating or mobilized LTC-IC relative to the normal marrow LTC-IC population or whether this is a unique feature of circulating PhLTC-IC in CML patients. The variable yields of expanded PhLTC-IC in culture suggest that there may be considerable heterogeneity in the numbers of functionally different subtypes of LTC-IC (or their precursors)22,32-34 that are spontaneously mobilized in different CML patients. Under the same culture conditions, Ph+LTC-IC were unable to maintain their functional state. This defective behavior of Ph+LTC-IC could be seen in cultures containing a variety of cytokine supplements (Tables 1 and 3) and occurred independent of whether or not normal LTC-IC were present (Table 6). In previous studies, we have shown that Ph+LTC-IC decrease 50-fold more rapidly than do normal LTC-IC, both under conditions used to initiate long-term cultures from bone marrow cells and when the cells are seeded onto preestablished marrow adherent layers.10,29 Under either of these conditions, which do not involve the provision of exogenous soluble cytokines, normal LTC-IC are maintained at input levels for 7 to 10 days, but do not expand. The fact that a marked loss of LTC-IC activity can also be demonstrated when Ph+LTC-IC are cultured in highly purified form and at low cell densities suggests that this abnormal behavior is intrinsically determined and not readily modulated by extracellular factors, including those involved in the interactions such cells have with stroma.35 

The mechanism underlying the loss of LTC-IC activity exhibited by cultured Ph+ cells has not yet been determined. For example, whether the loss of this activity is associated with cell death or, alternatively, with a change in proliferative potential, acquisition of an ability to proliferate in methylcellulose and/or cytokine responsiveness are all questions that will need to be addressed in future studies. Some groups have obtained evidence to indicate that the BCR-ABL gene product can confer an increased resistance to the apoptotic response that is normally induced by factor deprivation36-38 and others have suggested that CML cells may be characterized by a tendency to differentiate prematurely.39,40 We have recently shown that circulating Ph+LTC-IC represent a rapidly cycling population, in contrast to the LTC-IC that circulate in normal individuals, or the PhLTC-IC that are sometimes also detectable in the blood of CML patients.41,42 In addition, we have recently shown that BCR-ABL mRNA is present at detectable levels in all types of primitive Ph+ cells regardless of their phenotype.43 Taken together, these findings support a model of CML in which the Ph+ stem cell has two linked features: (1) an intrinsically increased ability to remain alive and proliferate under conditions that may promote the apoptosis or quiescence of normal stem cells, and (2) a decreased probability of self-renewal, ie, an increased probability of differentiation.44 Such a model could account for a number of observations of the behavior of the leukemic clone in vivo. These include the relatively long average latent period (≈7 years) before Ph+ clones typically attain a size sufficient for the development of clinical symptoms of disease,45 the delayed relapses (after >5 years) that are occasionally seen in CML patients previously “cured” of their disease by an allogeneic bone marrow transplant,46 and the rapid but transient resurgence of predominantly Ph hematopoiesis in patients given combination chemotherapy without a transplant.11 47 

Finally, the present experiments draw attention to the possibility of using cell separation in combination with defined culture conditions to improve current culture-purging approaches to reducing the leukemic stem cell burden in CML autotransplants.27,28 A procedure that involves a significant reduction in the number of cells to be cultured and, hence, the volumes to be handled could greatly facilitate the development of more widely applicable, safer, and cheaper closed systems for the routine manipulation of such transplants. The added advantage of being able to simultaneously amplify the normal stem cell content of the graft while purging residual CML stem cells would also be particularly attractive for use in patients where the starting population of normal stem cells may be limiting13 or where a gene transfer procedure is envisaged.

The excellent technical assistance of W. Dragowska and G. Thornbury for cell sorting and G. Shaw for performing the cytogenetic analyses is gratefully acknowledged. The authors also thank S. Clegg for expert assistance in preparing the manuscript; StemCell, Amgen (Thousand Oaks, CA), Immunex (Seattle, WA), and Sandoz (Basel, Switzerland) for generous gifts of reagents; and Dr P. Lansdorp for the 8G12-FITC antibody.

Supported by grants from the National Cancer Institute of Canada (NCIC) with funds from the Terry Fox Run and the Canadian Cancer Society (to C.J.E., A.C.E, and M.J.B.) and a grant (No. J1034-MED) from the E. Schrödinger Foundation (to A.L.P.). C.J.E. is a Terry Fox Cancer Research Scientist of the NCIC supported by funds from the Terry Fox Run.

Address reprint requests to A.C. Eaves, MD, PhD, Terry Fox Laboratory, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.

1
Raskind
WH
Fialkow
PJ
The use of cell markers in the study of human hematopoietic neoplasia.
Adv Cancer Res
49
1987
127
2
Groffen
J
Heisterkamp
N
The BCR/ABL hybrid gene.
Baillieres Clin Haematol
1
1987
983
3
Rowley
JD
A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
Nature
243
1973
290
4
Hariharan
IK
Adams
JM
Cory
S
BCR-ABL oncogene renders myeloid cell line factor independent: Potential autocrine mechanism in chronic myeloid leukemia.
Oncogene Res
3
1988
387
5
Daley
GQ
Van Etten
RA
Baltimore
D
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Science
247
1990
824
6
Heisterkamp
N
Jenster
G
ten Hoeve
J
Zovich
D
Pattengale
PK
Groffen
J
Acute leukemia in bcr/abl transgenic mice.
Nature
344
1990
251
7
Elefanty
AG
Hariharan
IK
Cory
S
bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.
EMBO J
9
1990
1069
8
Kelliher
MA
McLaughlin
J
Witte
ON
Rosenberg
N
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Proc Natl Acad Sci USA
87
1990
6649
9
Gishizky
ML
Johnson-White
J
Witte
ON
Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
Proc Natl Acad Sci USA
90
1993
3755
10
Coulombel
L
Kalousek
DK
Eaves
CJ
Gupta
CM
Eaves
AC
Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
N Engl J Med
308
1983
1493
11
Goto
T
Nishikori
M
Arlin
Z
Gee
T
Kempin
S
Burchenal
J
Strife
A
Wisniewski
D
Lambek
C
Little
C
Jhanwar
S
Chaganti
R
Clarkson
B
Growth characteristics of leukemic and normal hematopoietic cells in Ph1+ chronic myelogenous leukemia and effects of intensive treatment.
Blood
59
1982
793
12
Talpaz
M
Kantarjian
HM
McCredie
K
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia.
N Engl J Med
314
1986
1065
13
Eaves
C
Udomsakdi
C
Cashman
J
Barnett
M
Eaves
A
The biology of normal and neoplastic stem cells in CML.
Leuk Lymphoma
11
1993
245
14
Petzer
AL
Eaves
CJ
Lansdorp
PM
Ponchio
L
Barnett
MJ
Eaves
AC
Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia.
Blood
88
1996
2162
15
Carella
AM
Podesta
M
Frassoni
F
Raffo
MR
Pollicardo
N
Pungolino
E
Vimercati
R
Sessarego
M
Parodi
C
Rabitti
C
Ferrero
R
Benvenuto
F
Figari
O
Carlier
P
Levcasic
G
Valbonesi
M
Vitale
V
Giordano
D
Pierluigi
D
Nati
S
Guerracio
A
Rosso
C
Saglio
G
Collection of “normal” blood repopulating cells during early hematopoeietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
Bone Marrow Transplant
12
1993
267
16
Sirard
C
Lapidot
T
Vormoor
J
Cashman
JD
Doedens
M
Murdoch
B
Jamal
N
Messner
H
Addey
L
Minden
M
Laraya
P
Keating
A
Eaves
A
Lansdorp
PM
Eaves
CJ
Dick
JE
Normal and leukemic SCID-repopulating cells (SRC) co-exist in the bone marrow and peripheral blood from CML patients in chronic phase while leukemic SRC are detected in blast crisis.
Blood
87
1996
1539
17
Sutherland
HJ
Lansdorp
PM
Henkelman
DH
Eaves
AC
Eaves
CJ
Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers.
Proc Natl Acad Sci USA
87
1990
3584
18
Kalousek
DK
Eaves
CJ
Eaves
AC
In-vitro cytogenetic studies of haemopoietic malignancies.
Cancer Surv
3
1984
439
19
Civin
CI
Strauss
LC
Brovall
C
Fackler
MJ
Schwartz
JF
Shaper
JH
Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells.
J Immunol
133
1984
157
20
Terstappen
LWMM
Huang
S
Safford
M
Lansdorp
PM
Loken
MR
Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38− progenitor cells.
Blood
77
1991
1218
21
Issaad
C
Croisille
L
Katz
A
Vainchenker
W
Coulombel
L
A murine stromal cell line allows the proliferation of very primitive human CD34++/CD38− progenitor cells in long-term cultures and semisolid assays.
Blood
81
1993
2916
22
Sauvageau
G
Lansdorp
PM
Eaves
CJ
Hogge
DE
Dragowska
WH
Reid
DS
Largman
C
Lawrence
HJ
Humphries
RK
Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells.
Proc Natl Acad Sci USA
91
1994
12223
23
Petzer
AL
Hogge
DE
Lansdorp
PM
Reid
DS
Eaves
CJ
Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium.
Proc Natl Acad Sci USA
93
1996
1470
24
Verfaillie
CM
Miller
WJ
Boylan
K
McGlave
PB
Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression.
Blood
79
1992
1003
25
Udomsakdi
C
Eaves
CJ
Lansdorp
PM
Eaves
AC
Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia.
Blood
80
1992
2522
26
Verfaillie
CM
Bhatia
R
Miller
W
Mortari
F
Roy
V
Burger
S
McCullough
J
Stieglbauer
K
Dewald
G
Heimfeld
S
Miller
JS
McGlave
PB
BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Blood
87
1996
4770
27
Barnett
MJ
Eaves
CJ
Phillips
GL
Kalousek
DK
Klingemann
H-G
Lansdorp
PM
Reece
DE
Shepherd
JD
Shaw
GJ
Eaves
AC
Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture.
Bone Marrow Transplant
4
1989
345
28
Barnett
MJ
Eaves
CJ
Phillips
GL
Gascoyne
RD
Hogge
DE
Horsman
DE
Humphries
RK
Klingemann
H-G
Lansdorp
PM
Nantel
SH
Reece
DE
Shepherd
JD
Spinelli
JJ
Sutherland
HJ
Eaves
AC
Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study.
Blood
84
1994
724
29
Udomsakdi
C
Eaves
CJ
Swolin
B
Reid
DS
Barnett
MJ
Eaves
AC
Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level.
Proc Natl Acad Sci USA
89
1992
6192
30
Petzer
AL
Zandstra
PW
Piret
JM
Eaves
CJ
Differential cytokine effects on primitive (CD34+CD38−) human hematopoietic cells: Novel responses to flt3-ligand and thrombopoietin.
J Exp Med
183
1996
2551
31
Hogge
DE
Lansdorp
PM
Reid
D
Gerhard
B
Eaves
CJ
Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3 and granulocyte colony-stimulated factor.
Blood
88
1996
3765
32
Sutherland
HJ
Eaves
CJ
Eaves
AC
Dragowska
W
Lansdorp
PM
Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro.
Blood
74
1989
1563
33
Prosper
F
Stroncek
D
Verfaillie
CM
Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor.
Blood
88
1996
2033
34
Hao
QL
Thiemann
FT
Petersen
D
Smogorzewska
EM
Crooks
GM
Extended long-term culture reveals a highly quiescent and primitive human hematopoietic progentior population.
Blood
88
1996
3306
35
Verfaillie
C
Hurley
R
Bhatia
R
McCarthy
JB
Role of bone marrow matrix in normal and abnormal hematopoiesis.
Crit Rev Oncol Hematol
16
1994
201
36
Evans
CA
Owen-Lynch
J
Whetton
AD
Dive
C
Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
Cancer Res
53
1993
1735
37
Bedi
A
Zehnbauer
BA
Barber
J
Sharkis
S
Jones
R
Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.
Blood
83
1994
2038
38
Cortez
D
Kadlec
L
Pendergast
AM
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Mol Cell Biol
15
1995
5531
39
Strife
A
Lambek
C
Wisniewski
D
Wachter
M
Gulati
SC
Clarkson
BD
Discordant maturation as the primary biological defect in chronic myelogenous leukemia.
Cancer Res
48
1988
1035
40
Fokas
AS
Keller
JB
Clarkson
BD
Mathematical model of granulocytopoiesis and chronic myelogenous leukemia.
Cancer Res
51
1991
2084
41
Ponchio
L
Conneally
E
Eaves
C
Quantitation of the quiescent fraction of longterm culture-initiating cells (LTC-IC) in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro.
Blood
86
1995
3314
42
Ponchio L, Cashman J, Zoumbos N, Eaves CJ, Eaves A: Primitive CML cells show a deregulation of their cycling status both in vivo and in longterm cultures which is not normalized in the presence of interferon-α. Blood 86:493a, 1995 (abstr, suppl 1)
43
Maguer-Satta
V
Petzer
AL
Eaves
AC
Eaves
CJ
BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
Blood
88
1996
1796
44
Eaves
CJ
Cashman
JD
Zoumbos
NC
Barnett
MJ
Eaves
AC
Biological strategies for the selective manipulation of normal and leukemic stem cells.
Stem Cells
11
1993
109
45
Heyssel
R
Brill
AB
Woodbury
LA
Nishimura
ET
Ghose
T
Hoshino
T
Yamasaki
M
Leukemia in Hiroshima atomic bomb survivors.
Blood
15
1960
313
46
van Rhee
F
Lin
F
Cross
NCP
Reid
CDL
Lakhani
AKV
Szydlo
RM
Goldman
JM
Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia.
Bone Marrow Transplant
14
1994
609
47
Kantarjian
HM
Vellekoop
L
McCredie
KB
Keating
MJ
Hester
J
Smith
T
Barlogie
B
Trujillo
J
Freireich
EJ
Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia.
J Clin Oncol
3
1985
192
Sign in via your Institution